Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
AstraZeneca
Study ID
NCT06921785
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Key Dates

Start date
May 6, 2025
Status verified
Jun 2026
Primary completion
Mar 16, 2029
Completion
Mar 15, 2030

Study Design

Enrollment
1,220 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Tremelimumab , rilvegostomig and bevacizumab
  • Experimental: Arm B
    Rilvegostomig, and bevacizumab
  • Active Comparator: Arm C
    Atezolizumab, and bevacizumab

Primary Outcome Measure

To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC [ Time Frame: Up to approximately 6 years ]

Central Contacts

Locations (35)

FacilityCityStateZIPSite coordinators
Research SitePhoenixArizona85054-
Research SiteTucsonArizona85719-
Research SitePalo AltoCalifornia94304-
Research SiteSanta MonicaCalifornia90404-
Research SiteNew HavenConnecticut06520-
Research SiteNewarkDelaware19713-
Research SiteJacksonvilleFlorida32224-
Research SiteAtlantaGeorgia30318-
Research SiteAtlantaGeorgia30322-
Research SiteHonoluluHawaii96813-
Research SiteChicagoIllinois60637-
Research SiteIndianapolisIndiana46202-
Research SiteShreveportLouisiana71103-
Research SiteDetroitMichigan48202-
Research SiteGrand RapidsMichigan49503-
Research SiteRochesterMinnesota55905-
Research SiteSt LouisMissouri63110-
Research SiteNew BrunswickNew Jersey08901-
Research SiteNew YorkNew York10029-
Research SiteNew YorkNew York10032-
Research SiteNew YorkNew York10065-
Research SiteClevelandOhio44195-
Research SiteOklahoma CityOklahoma73104-
Research SitePhiladelphiaPennsylvania19107-
Research SitePittsburghPennsylvania15232-
Research SiteAmarilloTexas79124-
Research SiteAustinTexas78705-
Research SiteDallasTexas75390-
Research SiteHoustonTexas77030-
Research SiteSan AntonioTexas78240-
Research SiteTylerTexas75702-
Research SiteArlingtonVirginia22201-
Research SiteSalemVirginia24153-
Research SiteSeattleWashington98109-
Research SiteMilwaukeeWisconsin53226-

Find similar trials in Phoenix, AZ

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
Research Site· Phoenix, AZResearch Site· Tucson, AZResearch Site· Palo Alto, CAResearch Site· Santa Monica, CAResearch Site· New Haven, CTResearch Site· Newark, DE

Related Studies